All In Biotech

NDA 209092 · Novartis

Kisqali

Ribociclib Succinate · Oral

NovelBreakthrough therapyPriority review

Last checked: Nov 20, 2026Latest source record: Jul 1, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2017

Mar 13, 2017

Approved uses

8

Original approval plus efficacy supplements

Registered trials

194

38 Phase 3, 52 recruiting

FAERS reports

32,716

27,086 serious, 4,684 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 1, 2026.

KISQALI is a kinase inhibitor indicated: in combination with an aromatase inhibitor for the adjuvant treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II and III early breast cancer at high risk of recurrence. ( 1 ) for the treatment of adults with HR-positive, HER2-negative advanced or metastatic breast cancer in combination with: an aromatase inhibitor as initial endocrine-based therapy; or fulvestrant as initial endocrine-based therapy or following disease progression on endocrine therapy. ( 1 ) 1.1 Early Breast Cancer KISQALI is indicated in combination with an aromatase inhibitor for the adjuvant treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II and III early breast cancer at high risk of recurrence. 1.2 Advanced or Metastatic Breast Cancer KISQALI is indicated for the treatment of adults with HR-positive, HER2-negative advanced or metastatic breast cancer in combination with: an aromatase inhibitor as initial endocrine-based therapy; or fulvestrant as initial endocrine-based therapy or following disease progression on endocrine therapy.

Mechanism: Ribociclib is an inhibitor of cyclin-dependent kinase (CDK) 4 and 6. These kinases are activated upon binding to D-cyclins and are downstream of signaling pathways which lead to cell cycle progression and cellular proliferation. The cyclin D-CDK4/6 complex regulates cell cycle progression through phosphorylation of the retinoblastoma protein (pRb). In vitro , ribociclib decreased pRb phosphorylation, resulting in arrest in the G1 phase of the cell cycle and reduced proliferation in breast cancer-derived models. In vivo , treatment with single agent ribociclib in a rat xenograft model with...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • KISQALI · RIBOCICLIB SUCCINATE EQ 200MG BASE · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Ribociclib" as an intervention, any sponsor and status, largest first.

All 194 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • neutropenia4,342
  • fatigue3,986
  • nausea3,932
  • malignant neoplasm progression2,842
  • death2,554
  • vomiting2,210
  • diarrhoea2,125
  • white blood cell count decreased2,076
  • pain1,940
  • metastases to bone1,825
  • asthenia1,680
  • breast cancer metastatic1,678

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20143
20163
2017507
20181,211
20192,156
20203,064
20213,676
20224,013
20235,960
20243,887
20254,574
20263,662

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Kisqali (Ribociclib Succinate)

2024 spending

$775M

Beneficiaries

8,782

52,578 claims

Per beneficiary

$88,305

$296.84 per unit

View as table
YearSpending
2020$128,739,776
2021$119,293,640
2022$166,342,358
2023$370,771,679
2024$775,493,707

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 162 on PubMed

Sponsor: Novartis

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.